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Background and Aim: Increasing numbers of CF patients are making increasingly
diverse travel plans. Following the British Thoracic Society recommendations on air
travel from 2011 we reviewed our experience of Hypoxic Challenge Testing (HCT)
since its availability in our centre six years ago and reported adverse ﬂight events.
Method: FEV1% and saturations on room air (SpO2) were collected retrospectively
on all adult CF patients referred for HCT and any subsequent adverse ﬂight events
reported by patients noted. Previously described non linear equations were used to
try to predict HCT result.
Results: Of the 312 HCT performed 45 (17 male) were CF patients with mean age
27.3 years (range 16−47), FEV1%predicted 45.0±19.4% and SpO2 96.0±1.7%.
10/45 HCT were positive (5 male) of whom 9 had FEV1% <50% and 7 had SpO2
<95%. Using FEV1% <50 alone to predict a positive HCT has a sensitivity of 32%
and speciﬁcity of 94% and using SpO2 <95% alone has sensitivity and speciﬁcity
of 78% and 92%respectively. The nonlinear equations were no better than FEV1%
or SpO2 alone in predicting HCT outcome in this group. No adverse effects were
reported during air travel by patients.
Conclusion: Neither FEV1%, SpO2 or non linear equations appear to accurately
predict HCT result in our cohort and this reﬂects previous studies. However,
previous studies, although in small numbers, have also suggested hypoxia is
relatively well tolerated in patients with CF and no adverse effects were reported
by our patients. HCT itself does not predict ﬁtness to ﬂy and other factors such as
destination altitude, insurance provision, sinus disease and medical availability are
also clearly important.
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Objectives: Thick, tenacious secretions causing impaired mucocilliary clearance
& airway obstruction are a hallmark of CF. There is conﬂicting evidence about
the relative role of the major airway mucins MUC5AC & 5B in determining
physical properties of sputum. To investigate the role of MUC5AC & the effects
of proteolytic degradation, we have assessed CF sputum linear viscoelasticity
(rheology) and MUC5AC properties before & after incubation for 60 mins at 37ºC.
Methods: Whole sputum was collected from CF patients during an exacerbation.
Elastic moduli (G′) and dissipative moduli (G′′, related to viscosity) were calculated
on 100ml aliquots from a dynamic oscillatory test at 1Hz using a constant stress
of 1Pa. Mucins were solubilised in GnCl and MUC5AC amount & size distribution
analysed by agarose gel electrophoresis & Western blotting using the 5AC peptide-
speciﬁc antibody MAN5AC-I.
Results: Paired rheology data were obtained on 9 samples from 8 patients (median
age 23 yrs, median FEV1 28%). After incubation, G
′ fell from a mean of 7.98
to 3.99Pas (mean fall of 44%, p< 0.001). G′′ fell from 3.46 to 1.62 Pas (46%,
p< 0.001). Preliminary data on a subset indicate MUC5AC antibody reactivity fell
from mean [MUC5AC] 6.3 mg/ml to 3.9mg/ml, p< 0.05. In addition, there was a
shift towards lower molecular weight forms.
Conclusions: There was loss of MAN5AC-I epitopes in sputum samples over time,
indicating degradation of mucins by proteases within sputum and conﬁrmed by
altered electrophoretic migration. This may also be responsible for the observed
changes in sputum rheology. Work is ongoing to further characterise the relationship
between mucins & rheological properties of sputum.
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Airways-obstruction and lung volume restriction, a major features of lung disease
in cystic ﬁbrosis (CF), may regress independently, causing growing dysanapsis
between these parameters.
Objective: To explore longitudinal changes in mid-ﬂows to vital capacity
(FEF25−75/FVC) ratio in CF.
Methods: Yearly best spirometry data, collected 8.6±1.0 years/patient, was deter-
mined from 93 CF-patients. Three groups were formed according to initial FEV1.
Group-N (n = 35; control (FEV1 >80% predicted); Group-B (n = 38; FEV1 <80%
predicted); Group-LT (n = 20) data collected prior to lung transplantation. The yearly
declines in spirometry indices were deﬁned in relation to the former year. Decline
exceeding −2 Z-scores from Group-N in each index was considered “rapid”.
Results: Group-N’s yearly-decline of FEV1, FEF25−75 and FEF25−75/FVC were
similar (−1.88±2.93%; −1.41±3.37 and −1.81±4.48% respectively). Group-B’s
yearly decline-rate of FEV1 and FEF25−75 was faster than that of Group-N
but did not exceed a single Z-score. Group-LT showed a rapid decline solely in
FEF25−75/FVC (mean Z-score = −6.4±2.5; p< 0.0001) that sprouted abruptly
from the regular course of regression 4.0+1.3 yrs prior to transplantation. The
phenomenon did not correlate with initial FEV1 (%predicted) or age. Having airway
hyper-reactivity and/or Mycobacterium abscessus increased the risk of rapid decline
in FEF25−75/FVC.
Conclusions: Rapid decline of FEF25−75/FVC ratio several years prior to trans-
plantation may indicate irreversible lung damage and may be a powerful marker for
estimating that time in patients with CF.
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Objectives: Maximal cardiopulmonary exercise testing (CPET) assessing aerobic
metabolism [maximal O2 uptake (V˙O2max)] is an important clinical tool in cystic
ﬁbrosis (CF). However the optimal protocol to ensure valid determination of
V˙O2max has not been clariﬁed. The present study sought to examine the utility of
a supramaximal exercise test (Smax) following CPET to determine valid V˙O2max
in young CF patients.
Methods: Fourteen patients (7−18 y; 4 female, 10 male) completed an incremental
ramp cycle test to volitional exhaustion to determine their V˙O2peak . Following
15-min recovery a Smax cycling test to exhaustion was performed at an intensity
equivalent to 110% ramp peak power output. V˙O2peak was taken as the highest
15-s stationary average, in addition to traditional veriﬁcation criteria.
Results: Smax elicited a similar V˙O2peak to the ramp (1.815±0.688 vs. 1.825±0.821
L/min; P = 0.403; r = 0.94) in 73% of cases, despite exercising at a higher power
output (171±85 vs. 191±93 W). This was despite many patients failing to satisfy
traditional criterion during the original ramp test: V˙O2 plateau (79%); blood lactate
(23%), 85% age-predicted maximum heart rate (HR) (17%) and a HR of 195
beats/min (58%). However, all patients satisﬁed the RER >1.06 criterion.
Conclusions: In most cases, Smax can conﬁrm V˙O2max in this population. It is
recommended as the sole criterion for substantiating ‘true’ V˙O2max within future
clinical practice and scientiﬁc research as a clinically useful protocol to provide
superior information.
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